GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B2226 SKI IITarget: Sphingosine kinases (SphKs)Summary: Sphingosine kinase(SK) inhibitor
- B3240 AlmorexantSummary: OX1R/OX2R antagonist
- B3241 Almorexant hydrochlorideSummary: OX1R/OX2R antagonist
- B1424 NPS-2143Summary: CaSR antagonist
- B2166 TicagrelorSummary: P2Y12 receptor antagonist
- B2206 PD123319Target: Angiotensin AT2 ReceptorsSummary: Angiotensin AT2 receptor antagonist
- B2179 PF-05212384 (PKI-587)Summary: PI3Kα, PI3Kγ and mTOR inhibitor
- B1281 SB-334867 hydrochlorideSummary: Orexin-1 receptor antagonist
- B1044 TCS 1102Summary: Antagonist for OX2 and OX1 receptors
- B1137 GSK962040 hydrochlorideSummary: Small molecule, selective motilin receptor agonist